S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
This MMJ Stock Needs To Be At The Top Of Your Radar! (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Central Bank: “Final stage” beginning now (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain

Best Stocks Under $5.00 Right Now

Best Stocks Under $5.00

Like any group of stocks, penny stocks require discerning between price and value

There is a primal attraction to stocks priced under $5. These stocks are also known as penny stocks. Some purists will suggest that penny stocks have to trade for less than $1. However, in recent years, investors generally accept the definition that any stock that consistently trades below $5 fits into the category of penny stocks.

In this article, we’ll explain why stocks under $5 are considered penny stocks and whether investors should invest in penny stocks at all. We’ll also outline some of the risks and the rewards of buying stocks under $5. And we’ll provide some tips for successfully trading these stocks.

As mentioned above, penny stocks are stocks that trade for $5 or less. This definition means there are many options for investors including dollar stocks, penny stocks, and stocks that sell for fractions of one penny.

One stereotype about penny stocks is that every company is a startup that is in a risky market sector. However, there are many established businesses trading on standard exchanges that trade for less than $5 per share. When these companies appear on major exchanges, they are viewed as carrying less risk because they have to meet regulatory requirements that keep their accounting transparent.

That being said, penny stocks are usually small-cap companies (i.e. those with a market capitalization of less than $2 billion) that are either new to the market or undervalued and not recognized by investors. There tend to be fewer shares of these stocks available, meaning there is usually a wider spread between bids and asking prices.

And because penny stocks are generally considered to be speculative investments, they carry a certain element of risk. But it’s this risk that provides the opportunity for investors to make significant gains.

A broader question might be, “Should you buy stocks at all?” The answer to both questions is the same: It depends. You should not buy stocks if you don’t have a discriminating sense of how to invest money, or if you don’t have guidance around the topic from someone who does.

With the right knowledge, stocks are an excellent investment, and according to some estimates, far more sound than real estate. Yes, stock prices do fluctuate (sometimes wildly), but over the last several decades, they have outperformed real estate in some regards.

And investors who know what they’re doing with stocks can make huge gains, build enormous wealth, and create exponential financial success. Stocks under $5, in particular, present an incredible opportunity to make huge gains.

It all comes down to research.

You never want to sink all of your investment cash into just one basket. Estimates vary on the exact percentage, but most experts agree that the majority of your portfolio should be invested in solid, stable companies. That said, stocks under $5 can be a good place to do a little value investing and give some growth to your cash.

It’s important to keep in mind that there are many trading strategies in relation to the stock market, and investing in undervalued, up-and-coming companies is only one strategy. For example, some investors prefer to focus on stocks that pay out dividends, where each share pays out dividend payments of company profit—and a large number of shares creates a solid cash flow. Other investors like to buy shares in specific industries, like tech stocks, or they may choose to ride the market as they engage in the ups and downs of day trading, flipping stocks for profit.

Whichever stock trading strategy you prefer, penny stocks can be some of the best growth stocks for their undervalued cost—if you trade the right way.

As mentioned, penny stocks present huge opportunities for growth. Take True Religion as an example—an apparel company based in Vancouver, Canada. This designer-jeans outfit was trading for $0.67 per share in July of 2004. Just nine years later, TowerBrook Capital Partners acquired the company and paid $32 for every share...a whopping 4676% profit.

Can you think of any “normal stocks” that offered investors the same gains? They’re few and far between (though they do exist). These are the types of profit margins that traders dream of earning.

Another advantage of penny stocks is that they can be an easy way for small-time investors to enter the market. You don’t necessarily have to sink everything into some sort of risky biotech company. There are plenty of brand-name companies that are trading at under $5. Purchasing shares of these recognized businesses could be your chance to enter the stock market in an affordable way—and cash out big if things work out.

It’s not just about price, but about volume: A $500 investment might only buy you 5-10 shares of a recognizable blue-chip stock or it could buy you 100+ shares of a stock priced at $5 and below. If that company grows and becomes a mid-cap stock, you’ll see a lot more profit than you would have by investing in a more “normal” stock.

For that very same reason, penny stocks may allow you to diversify your holdings to a greater extent, with less money (if you want to eschew mutual funds and pick stocks yourself). With just $100 in the market, you could buy ten shares of stock in ten different industries.

Many stocks under $5 are companies that may be startups or riskier business ventures. One of the biggest examples is biotech, an industry with larger startup costs and huge risks for investors. A startup company may discover the cure for cancer, in which case, you can cash out as a billionaire. Or, they may not, and they’ll take all your money with them when they fold.

Another disadvantage to stocks under $5 is that they may be stocks of a company that’s about to go bankrupt. They could be desperately selling shares of stock to raise money, or to help their executives bail out with a parachute built from your investment. Newly formed startups may also be on the verge of bankruptcy, and because of their lack of established history, no one may even know.

Occasionally penny stocks will be part of a “pump and dump” scam, where investors build excitement over a particular stock to drive up the price. They may “leak” information that a startup energy company struck gold or put forth an imaginative but enticing earnings estimate for the next quarter. As the stock value climbs out of control (far beyond the actual value of the market cap), hoodwinked investors pour their dollars into the company. Then it crashes, and the only ones who benefit are the scammers who bought into the stock before they made it popular.

Another more prosaic risk of stocks under $5 is that they may just not go anywhere, hovering under $5 for years on end. While this is certainly better than losing all your money, it’s not so conducive to portfolio growth.

Yet another disadvantage to stocks under $5 is their low trading volume. They can be harder to unload if you need to, because you may not find a willing buyer. Moreover, many penny stocks of younger upstart companies will most likely not pay out dividends. You are only purchasing the stock to leverage a change in its price—or hoping that in the future they will play into your dividend investing strategy.

As you can see, there are some risks and volatility associated with stocks under $5. However, it once again all comes down to playing it smart and doing your research. There are plenty of resources which will tell you about the most volatile stocks, along with providing stats to gauge their future possibilities.

If you have a good head for what’s going on, you won’t fall for scams or pour all your money into a pipe dream. The best traders know which stocks to watch; they understand the ins and outs of dividend yield and market capitalization—and can leverage these stats into higher amounts of revenue. There’s no secret to what they’re doing. They’re actively learning and keeping their eyes on the best times to buy stocks at 52 week low points. They know when to hold their assets, and when to sell them.

Some stocks under $5 are traded on the New York Stock Exchange and NASDAQ. However, most stocks under $5 trade through over the counter transactions (OTC). Everything about these OTC transactions is done electronically through the OTC Bulletin Board (OTCBB). Companies that are traded on the OTCBB must still meet requirements from the SEC and FINRA. However, these companies don’t meet the requirements for trading on a larger market.

There are still more stocks under $5 that don’t even meet the requirements to be traded on the OTCBB. These stocks can be found on a listing service called Pink Sheets (so named because the stocks were once listed on pink sheets of paper). These companies are too small to be listed on a national exchange, or may not wish to make their accounting statements public—which means they don’t have to file with the SEC, and can’t be listed on a publicly-traded market.

As you might expect, these Pink Sheet stocks can carry significant risks. They can be difficult to analyze because of the lack of transparency around their business; investors should use caution and due diligence when purchasing them.

Now that we’ve reviewed the pros and cons of stocks under $5 and explained how they work, let’s address the question that every investor wants to know: how do I actualize this information?

It can be hard to find good stocks under $5, particularly in bull markets. This is a time when stocks frequently hit new all-time highs, and the price-to-earnings ratios of most S&P 500 companies make purchasing shares look like an expensive proposition. For these and other reasons, many investors have trouble finding low-priced stocks that haven't already appreciated greatly.  In more normal markets, a typical S&P 500 company trades at about fifteen times their earnings.

However, value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $5 requires investors to look at smaller and riskier companies in sectors that are either undiscovered or unrecognized by the market as a whole. When looking at cheap stocks to buy, some of them may not look especially attractive today, but long-term investors will recognize profit if they are willing to exercise patience and hold onto shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are small. As a result, they’re considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unrecognized or untested areas of the market. You may find even find crypto stocks, marijuana stocks, and bitcoin stocks on this list. Others have been beaten up by Mr. Market after a long period of slowing profits but are now actively trying to turn around their business and bounce back.

This low-priced list of stocks showcases a lot of different industries, but these picks all carry two common characteristics: They all have a super-low share price of $5.00 or less, and they all consistently receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


JD Sports Fashion stock logo

#1 - JD Sports Fashion

OTCMKTS:JDSPY
Stock Price: $2.39 (+$0.04)
Average Trading Volume: 2,469 shares
Consensus Rating: Strong Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $203.33 (8,407.7% Upside)
JD Sports Fashion Plc retails and distributes sports fashion wear and outdoor clothing and equipment. It operates through the Sports Fashion and Outdoor segments. The Sports Fashion segment consists of JD Sports Fashion Plc, John David Sports Fashion (Ireland) Limited, Spodis SA, Champion Sports Ireland, JD Sprinter Holdings 2010 SL, JD Sports Fashion BV, JD Sports Fashion Germany GmbH, JD Sports Fashion SRL, Duffer of St George Limited, Topgrade Sportswear Limited, Kooga Rugby Limited, Focus Brands Limited, Kukri Sports Limited, Source Lab Limited, R.D. Scott Limited, Tessuti Group Limited, Nicholas Deakins Limited, Cloggs Online Limited, Ark Fashion Limited and Mainline Menswear Limited. The Outdoor segment consists of Blacks Outdoor Retail Ltd. Tiso Group Ltd and ActivInstinct Limited. The company was founded by John Carruthers Wardle and David Martin Makin in 1981 and is headquartered in Bury, the United Kingdom.
InflaRx stock logo

#2 - InflaRx

NASDAQ:IFRX
Stock Price: $4.57 (+$0.20)
PE Ratio: -7.37
Market Cap: $204.28 million
Average Trading Volume: 1.65 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $14.00 (206.3% Upside)
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
ORIC Pharmaceuticals stock logo

#3 - ORIC Pharmaceuticals

NASDAQ:ORIC
Stock Price: $4.96
PE Ratio: -2.26
Market Cap: $223.65 million
Average Trading Volume: 214,551 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.20 (166.1% Upside)
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
D-Wave Quantum stock logo

#4 - D-Wave Quantum

NYSE:QBTS
Stock Price: $0.48 (-$0.13)
Market Cap: $61.56 million
Average Trading Volume: 1.69 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.00 (932.8% Upside)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Launch, a quantum computing onboarding service; Ocean a full suite of open-source programming tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community. It also provides D-Wave Launch, a quantum professional service that guides enterprises from problem discovery through in-production application deployment. The company's quantum solutions are used in artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. It serves manufacturing and logistics, financial services, life sciences, and other industries. D-Wave Quantum Inc. is based in Burnaby, Canada.
DarioHealth stock logo

#5 - DarioHealth

NASDAQ:DRIO
Stock Price: $3.75 (-$0.02)
PE Ratio: -2.60
Market Cap: $98.85 million
Average Trading Volume: 154,219 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.40 (204.0% Upside)
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.
OmniAb stock logo

#6 - OmniAb

NASDAQ:OABI
Stock Price: $3.86 (-$0.06)
Market Cap: $446.22 million
Average Trading Volume: 640,177 shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.00 (159.1% Upside)
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
CarParts.com stock logo

#7 - CarParts.com

NASDAQ:PRTS
Stock Price: $4.20 (-$0.14)
PE Ratio: -105.00
Market Cap: $236.59 million
Average Trading Volume: 720,352 shares
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.00 (185.7% Upside)
CarParts.com, Inc. operates as an online provider of aftermarket auto parts and accessories in the United States and the Philippines. Its products include Collision Parts, Engine Parts, Performance Parts and Accessories. The firm also sells auto parts to collision repair shops, markets Kool-Vue products to auto parts wholesale distributor, and aftermarket catalytic converters under the Evan Fischer brand. Its flagship Websites include www.carparts.com, www.jcwhitney.com, www.autopartswarehouse.com and www.usautoparts.com. The company was founded by Sol Khazani and Mehran Nia in 1995 and is headquartered in Carson, CA.
Fusion Pharmaceuticals stock logo

#8 - Fusion Pharmaceuticals

NASDAQ:FUSN
Stock Price: $4.29 (+$0.04)
PE Ratio: -2.16
Market Cap: $273.92 million
Average Trading Volume: 263,494 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.67 (102.0% Upside)
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Backblaze stock logo

#9 - Backblaze

NASDAQ:BLZE
Stock Price: $4.30 (+$0.10)
PE Ratio: -2.50
Market Cap: $147.49 million
Average Trading Volume: 102,817 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.70 (148.8% Upside)
Backblaze, Inc., a storage cloud platform, provides businesses and consumers cloud services to store, use, and protect data in the United States and internationally. The company offers cloud services through a web-scale software infrastructure built on commodity hardware. It also provides Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. This service is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases, such as backups, multi-cloud, application development, and ransomware protection. In addition, the company offers Backblaze Computer Backup that automatically backs up data from laptops and desktops for businesses and individuals, which provides a subscription-based Software-as-a-Service and serves use cases, including computer backup, ransomware protection, theft and loss protection, and remote access. It serves the public cloud IaaS storage and Data-Protection-as-a-Service markets. The company was incorporated in 2007 and is headquartered in San Mateo, California.
Caribou Biosciences stock logo

#10 - Caribou Biosciences

NASDAQ:CRBU
Stock Price: $4.34 (+$0.08)
PE Ratio: -2.44
Market Cap: $266.32 million
Average Trading Volume: 507,192 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $27.60 (535.9% Upside)
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Thorne HealthTech stock logo

#11 - Thorne HealthTech

NASDAQ:THRN
Stock Price: $4.37 (-$0.01)
PE Ratio: 23.00
Market Cap: $235.36 million
Average Trading Volume: 47,787 shares
P/E Ratio: 23.0
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.92 (58.3% Upside)
Thorne HealthTech, Inc., a science-driven wellness company, provides solutions and personalized approaches to health and wellness in the United States and internationally. It offers various health tests, such as sleep, stress, weight management, gut health, heavy metals, biological age, and other health tests that generate molecular portraits for its customers, as well as develops nutritional supplements and offers wellness education solutions. The company uses the Onegevity platform to map, integrate, and understand the biological features that describe the state of an individual's health, as well as provide actionable insights and personalized data, products, and services that help individuals to take a proactive approach to improve and maintain their health. It primarily serves healthcare professionals, professional athletes, and professional sports and Olympic teams. Thorne HealthTech, Inc. was founded in 1984 and is headquartered in New York, New York.
Payoneer Global stock logo

#12 - Payoneer Global

NASDAQ:PAYO
Stock Price: $4.45 (+$0.05)
PE Ratio: -55.63
Market Cap: $1.58 billion
Average Trading Volume: 3.02 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.08 (81.6% Upside)
Payoneer Global Inc. operates a payment and commerce-enabling platform that facilitates marketplaces, platforms and online merchants worldwide. It delivers a suite of services that includes cross-border payments, B2B accounts payable/accounts receivable, multi-currency account, physical and virtual Mastercard cards, working capital, merchant, tax, compliance and risk, and others. The company's platform delivers bank-grade security, stability, and redundancy combined with modern digital capabilities that interconnects the world on a single platform. Its cross-border payment solutions support an ecosystem of marketplaces and marketplace sellers to pay their sellers in approximately 190 countries and territories by connecting to Payoneer APIs and for sellers to get paid. The company was founded in 2005 and is based in New York, New York.
Unity Biotechnology stock logo

#13 - Unity Biotechnology

NASDAQ:UBX
Stock Price: $2.83 (-$0.11)
PE Ratio: -0.56
Market Cap: $40.64 million
Average Trading Volume: 377,536 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.50 (129.7% Upside)
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
Checkpoint Therapeutics stock logo

#14 - Checkpoint Therapeutics

NASDAQ:CKPT
Stock Price: $2.87 (+$0.13)
Market Cap: $37.17 million
Average Trading Volume: 276,943 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $31.00 (980.1% Upside)
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
Autolus Therapeutics stock logo

#15 - Autolus Therapeutics

NASDAQ:AUTL
Stock Price: $2.94 (+$0.19)
PE Ratio: -2.12
Market Cap: $508.83 million
Average Trading Volume: 589,740 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.20 (178.9% Upside)
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Whole Earth Brands stock logo

#16 - Whole Earth Brands

NASDAQ:FREE
Stock Price: $3.06 (+$0.11)
PE Ratio: -1.58
Market Cap: $129.29 million
Average Trading Volume: 413,481 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.85 (189.2% Upside)
Act II Global Acquisition Corp. is a blank check company. It intends to focus on the business of following sector: consumer packaged goods, consumables and hospitality including restaurants. The company was founded on August 16, 2018 and is headquartered in New York, NY.
FTC Solar stock logo

#17 - FTC Solar

NASDAQ:FTCI
Stock Price: $3.08 (+$0.06)
PE Ratio: -3.76
Market Cap: $344.02 million
Average Trading Volume: 1.29 million shares
Consensus Rating: Buy (5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.14 (34.5% Upside)
FTC Solar, Inc. provides solar tracker systems, technology, software, and engineering services in the United States, Vietnam, and internationally. It offers two-panel in-portrait single-axis tracker solutions under the Voyager brand name. The company also provides SunPath, a software solution to enhance energy production; Atlas, a web-based enterprise-level database that allows users to manage their project portfolio; and SunDAT, a software solution enables automated design and optimization of solar panel systems across residential, commercial, and utility-scale sites. Its customers include project developers; solar asset owners; and engineering, procurement, and construction contractors that design and build solar energy projects. FTC Solar, Inc. was incorporated in 2017 and is headquartered in Austin, Texas.
SomaLogic stock logo

#18 - SomaLogic

NASDAQ:SLGC
Stock Price: $3.10 (+$0.08)
PE Ratio: -4.13
Market Cap: $582.46 million
Average Trading Volume: 1.02 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.20 (132.3% Upside)
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.
Compass Therapeutics stock logo

#19 - Compass Therapeutics

NASDAQ:CMPX
Stock Price: $3.17 (+$0.11)
PE Ratio: -8.81
Market Cap: $401.03 million
Average Trading Volume: 366,341 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $9.05 (185.5% Upside)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Century Therapeutics stock logo

#20 - Century Therapeutics

NASDAQ:IPSC
Stock Price: $3.21 (+$0.02)
PE Ratio: -1.49
Market Cap: $191.26 million
Average Trading Volume: 167,270 shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $19.00 (491.9% Upside)
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Mind Medicine (MindMed) stock logo

#21 - Mind Medicine (MindMed)

NASDAQ:MNMD
Stock Price: $3.35 (+$0.20)
PE Ratio: -1.83
Market Cap: $127.51 million
Average Trading Volume: 497,134 shares
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $26.67 (696.0% Upside)
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in New York, New York.
Sangoma Technologies stock logo

#22 - Sangoma Technologies

NASDAQ:SANG
Stock Price: $3.60 (-$0.13)
PE Ratio: -1.14
Market Cap: $86.04 million
Average Trading Volume: 10,227 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.25 (268.1% Upside)
Sangoma Technologies Corp. engages in the provision of value-based Communications as a Service (CaaS) solutions for businesses. The firm's CaaS offerings include Unified Communications as a Service, Trunking as a Service, Contact Center as a Service, Communications Platform as a Service, Video Meetings as a Service, Collaboration as a Service, Desktop as a Service, and Access Control as a Service. The company was founded by David Mandelstam in 1984 and is headquartered in Markham, Canada.
Endeavour Silver stock logo

#23 - Endeavour Silver

NYSE:EXK
Stock Price: $3.24 (-$0.01)
PE Ratio: -324.00
Market Cap: $620.49 million
Average Trading Volume: 2.52 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.83 (80.0% Upside)
Endeavour Silver Corp. operates as a mineral company. It engages in the evaluation, acquisition, exploration, development and exploitation of precious metal properties in Mexico and Chile. The firm's projects include the Terronera property in Jalisco, the El Compas property, the Guanacevi Mine in Durango, Bolanitos Mines in Guanajuato, and the Parral project in Chihuahua, Mexico. The company was founded by Bradford James Cooke on March 11, 1981 and is headquartered in Vancouver, Canada.
Terran Orbital stock logo

#24 - Terran Orbital

NYSE:LLAP
Stock Price: $1.50
PE Ratio: -1.46
Market Cap: $217.53 million
Average Trading Volume: 4.92 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.75 (616.7% Upside)
Terran Orbital Corporation manufactures, owns, and operates satellites and related space-based solutions that provide earth observation, data and analytics to defense, intelligence, civil, and commercial end users in the United States. The company operates through two segments, Satellite Solutions and Earth Observation Solutions. The Satellite Solutions segment offers end-to-end satellite solutions, including spacecraft design, development, launch services, and on-orbit operations for critical missions across a range of applications in various orbits to governmental agencies and commercial businesses. The Earth Observation Solutions segment develops, builds, launches, and operates a constellation of earth observation satellites that has synthetic aperture radar and electro-optical capabilities to provide earth observation data and mission solutions. It also provides secondary payload solutions and onboard data processing capabilities on its satellite constellation, including sensors, optical links, or other mission solutions. The company was founded in 2013 and is headquartered in Boca Raton, Florida.
AcuityAds stock logo

#25 - AcuityAds

NYSE:ATY
Stock Price: $1.60 (+$0.03)
PE Ratio: -159.84
Market Cap: $90.92 million
Average Trading Volume: 56,165 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.43 (114.3% Upside)
AcuityAds Holdings, Inc. engages in the provision of digital advertising solutions. It operates through the following geographical segments: Unites States, Canada, and Europe and Other. The company was founded by Tal Hayek, Nathan Mekuz, Rachel Kapcan, and Joe Ontman on October 9, 2009 and is headquartered in Toronto, Canada.

More Stock Ideas from MarketBeat

My Account -